Cargando…
SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia
BACKGROUND: We screened out several hypermethylated solute carrier (SLC) family genes in acute myeloid leukemia by reduced representation bisulfite sequencing. SLC22A3 encodes an organic cation transport protein, which is critical for drug transportation and cellular detoxification. SLC22A3 is signi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716704/ https://www.ncbi.nlm.nih.gov/pubmed/36461046 http://dx.doi.org/10.1186/s13148-022-01373-w |
_version_ | 1784842749651976192 |
---|---|
author | Gu, Yu Xu, Zi-jun Zhou, Jing-dong Wen, Xiang-mei Jin, Ye Yuan, Qian Xia, Pei-hui Feng, Yuan Yang, Lei Lin, Jiang Qian, Jun |
author_facet | Gu, Yu Xu, Zi-jun Zhou, Jing-dong Wen, Xiang-mei Jin, Ye Yuan, Qian Xia, Pei-hui Feng, Yuan Yang, Lei Lin, Jiang Qian, Jun |
author_sort | Gu, Yu |
collection | PubMed |
description | BACKGROUND: We screened out several hypermethylated solute carrier (SLC) family genes in acute myeloid leukemia by reduced representation bisulfite sequencing. SLC22A3 encodes an organic cation transport protein, which is critical for drug transportation and cellular detoxification. SLC22A3 is significantly downregulated and associated with tumor progression and worse prognosis in a variety of solid tumors. However, there are no data available regarding the role of SLC22 in AML. This study aimed to explore the regulatory mechanism of DNA methylation on SLC22A3 expression, as well as its clinical significance in AML prognosis. RESULTS: SLC22A3 was identified as the sole prognosis-associated gene among SLCs based on TCGA and Beat AML databases. Bone marrow mononuclear cells (BMMNCs) from AML, MDS patients, and healthy donors were enrolled in this study. SLC22A3 methylation was significantly increased in AML compared with controls and MDS patients; meanwhile, the expression level of SLC22A3 was decreased. SLC22A3 hypermethylation presented an obvious association with some specific clinical characteristics and affected the survival time of AML patients as an independent risk indicator. SLC22A3 expression changed regularly as the disease complete remissions and relapses. Demethylation drug 5-aza-2′-deoxycytidine (DAC) activated transcription and increased mRNA expression of SLC22A3 in leukemia cell lines and AML fresh BMMNCs. Knockdown of SLC22A3 in leukemia cells enhanced cell proliferation and suppressed cell apoptosis. Data from public programs were used for auxiliary screening of probable molecular mechanisms of SLC22A3 in the antileukemia effect. CONCLUSIONS: Our results showed that increased methylation and decreased expression of SLC22A3 may be indicators of poor prognosis in AML. Methylation-silenced SLC22A3 expression may have potential guiding significance on antileukemia effect of DAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01373-w. |
format | Online Article Text |
id | pubmed-9716704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97167042022-12-03 SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia Gu, Yu Xu, Zi-jun Zhou, Jing-dong Wen, Xiang-mei Jin, Ye Yuan, Qian Xia, Pei-hui Feng, Yuan Yang, Lei Lin, Jiang Qian, Jun Clin Epigenetics Research BACKGROUND: We screened out several hypermethylated solute carrier (SLC) family genes in acute myeloid leukemia by reduced representation bisulfite sequencing. SLC22A3 encodes an organic cation transport protein, which is critical for drug transportation and cellular detoxification. SLC22A3 is significantly downregulated and associated with tumor progression and worse prognosis in a variety of solid tumors. However, there are no data available regarding the role of SLC22 in AML. This study aimed to explore the regulatory mechanism of DNA methylation on SLC22A3 expression, as well as its clinical significance in AML prognosis. RESULTS: SLC22A3 was identified as the sole prognosis-associated gene among SLCs based on TCGA and Beat AML databases. Bone marrow mononuclear cells (BMMNCs) from AML, MDS patients, and healthy donors were enrolled in this study. SLC22A3 methylation was significantly increased in AML compared with controls and MDS patients; meanwhile, the expression level of SLC22A3 was decreased. SLC22A3 hypermethylation presented an obvious association with some specific clinical characteristics and affected the survival time of AML patients as an independent risk indicator. SLC22A3 expression changed regularly as the disease complete remissions and relapses. Demethylation drug 5-aza-2′-deoxycytidine (DAC) activated transcription and increased mRNA expression of SLC22A3 in leukemia cell lines and AML fresh BMMNCs. Knockdown of SLC22A3 in leukemia cells enhanced cell proliferation and suppressed cell apoptosis. Data from public programs were used for auxiliary screening of probable molecular mechanisms of SLC22A3 in the antileukemia effect. CONCLUSIONS: Our results showed that increased methylation and decreased expression of SLC22A3 may be indicators of poor prognosis in AML. Methylation-silenced SLC22A3 expression may have potential guiding significance on antileukemia effect of DAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01373-w. BioMed Central 2022-12-02 /pmc/articles/PMC9716704/ /pubmed/36461046 http://dx.doi.org/10.1186/s13148-022-01373-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Gu, Yu Xu, Zi-jun Zhou, Jing-dong Wen, Xiang-mei Jin, Ye Yuan, Qian Xia, Pei-hui Feng, Yuan Yang, Lei Lin, Jiang Qian, Jun SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia |
title | SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia |
title_full | SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia |
title_fullStr | SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia |
title_full_unstemmed | SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia |
title_short | SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia |
title_sort | slc22a3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716704/ https://www.ncbi.nlm.nih.gov/pubmed/36461046 http://dx.doi.org/10.1186/s13148-022-01373-w |
work_keys_str_mv | AT guyu slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT xuzijun slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT zhoujingdong slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT wenxiangmei slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT jinye slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT yuanqian slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT xiapeihui slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT fengyuan slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT yanglei slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT linjiang slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia AT qianjun slc22a3methylationmediatedgenesilencingpredictsadverseprognosisinacutemyeloidleukemia |